Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
TERAZOL 3 is a vaginal suppository antifungal approved in 1988 for treatment of vulvovaginal candidiasis. The product is a small-molecule therapeutic delivered topically to treat fungal infections in women. Mechanism of action targets fungal cell membrane integrity through azole class inhibition.
Product approaching loss of exclusivity with moderate competitive pressure (30/100); expect brand team consolidation and shift toward defensive positioning and lifecycle extension strategies.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on TERAZOL 3 offers career exposure to mature product lifecycle management, including generic transition strategy, cost containment, and market positioning. This role emphasizes commercial acumen and defensive strategy over growth-stage innovation, appealing to professionals seeking operational and tactical experience rather than portfolio expansion.
Worked on TERAZOL 3 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.